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The production and use of multi-modal imaging agents is on the rise. The vast
majority of these imaging agents are limited to a single length for the agent, which
is typically at the organ or tissue scale. This work explores the synthesis of such an
imaging agent and discusses the applications of our vitamin E-inspired multi-modal
and multi-length scale imaging agents TB-Toc ((S,E)-5,5-difluoro-7-(2-(5-((6-hydroxy-
2,5,7,8-tetramethylchroman-2-yl)methyl)thiophen-2-yl)vinyl)-9-methyl-5H-dipyrrolo-[1,2-
c:2’,1’-f][1,3,2]diazaborinin-4-ium-5-uide))). We investigate the toxicity of TB-Toc along
with the starting materials and lipid based delivery vehicle in mouse myoblasts and fi-
broblasts. Further we investigate the uptake of TB-Toc delivered to cultured cells in
both solvent and liposomes. TB-Toc has low toxicity, and no change in cell viability
was observed up to concentrations of 10 mM. TB-Toc shows time-dependent cellular
uptake that is complete in about 30 minutes. This work is the first step in realizing our
vitamin E derivatives as viable multi-modal and length scale diagnostic tools.
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Introduction
Multi-modal imagining is a sound diagnostic strategy with clinical applications in oncol-
ogy, cardiology and neuropsychiatry.1 Such imaging combines the strengths of the different
modalities into the same tissue of interest, providing additional contrast to quantify or local-
ize the site of disease. The vast majority of these multi-modal strategies combine standard
medical imaging techniques such as computed tomography (CT), magnetic resonance (MR)
and positron emission tomography (PET). Imaging agents that can be used across multiple
modalities at the same time can simplify pharmacological aspects of administering image
enhancing compounds, while providing anatomical as well as functional information. How-
ever, these well studied multi-modal strategies (PET, CT, MR) and their associated imaging
agents always provide images at similar length scales and resolutions.
Recently, efforts have been made in the area of multi-scale imaging agents (MIA).2–5
Multi-scale imaging provides separate images at different length scales; from the molecular
or cellular level, to the organ or whole organism level (Figure 1). Multi-scale imaging of
living systems has implications in all areas of medicine, such as mechanistic in vivo research,
biomarker discovery, early diagnosis and personalized medicine. The purpose of a multi-scale
imaging agent is thus to provide qualitative functional and localized information from the
organ level down to the cellular level. Light microscopy can be used to track the cellular
effects of a treatment or disease, while conventional medical imaging can reveal the organism
or tissue level context for the changes seen at the cellular level. Typically, light microscopy
cannot happen in situ, and specimen collection for separate analysis is required. Thus,
to ensure that the same biological context is being imaged at both length scales, the same
molecule must provide the image contrast at both length scales simultaneously. For example,
a molecule may be a beta particle emitter (for PET imaging) and fluorescent (for microscopy
imaging) at the same time.
Advances in cancer diagnosis and treatment are being led by improvements in MIAs that
enhance the ability to track diseases through pictures generated with injected radioactive
2
Figure 1: Multiscale imaging.
biomarkers. Advancements in molecular imaging, with positron emission tomography (PET)
leading the way, provide clinicians with improved diagnostic power.
The usefulness of a radiotracer in cancer diagnosis is limited by a number of factors,
including how well it is taken up by the body and the tumor, diagnostic reproducibility
and specificity (no false positives or negatives), and overall safety. Currently, 96% of PET
imaging is performed using just one compound, fludeoxyglucose (FDG), which targets cancer
in a non-specific manner. FDG has limitations in detecting certain types of tumors and can
accumulate in otherwise healthy areas of the body where it contributes to false positives and
delivers a significant radioactive dose to the patient. Despite these limitations, the usefulness
of PET is best demonstrated by current data suggesting that in as many as one-third to one-
half of cancer cases, physicians who do not have access to PET may be choosing the wrong
management or treatment strategy for their patients.6–8 A recent Canadian study found that
the information derived from PET imaging resulted in a change in intended treatment plans
in 50% of cases.9
Thus, there has been a tremendous amount of research on PET radio-tracers that can
improve on FDG. Take-up of newly designed radio-tracers by different tissues can be quickly
quantified by screening radioactivity levels, however we argue that in the rational design
of such molecules a better approach is to understand the reasons for take-up or rejection
by cancer cells versus healthy cells. For example, live cell fluorescence microscopy can be
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employed to visualize the incorporation of a candidate molecule into normal or cancer cells.
However, this requires that the radio-tracers to be fluorescent so they can be visualized
optically at such small length scales.
The use of fluorescence microscopy to observe absorption and intracellular transportation
of a labeled molecule can be achieved with photo-stable fluorescent probes. In particular,
probes with a fluorophore that absorbs at wavelengths greater than ∼500 nm makes for
better light penetration in cells and tissues within a patient. Furthermore, the fluorophore
should be photo-stable during the course of this irradiation – a well-known property of the
BODIPY family of compounds.10 BODIPY dyes are notable for their uniquely small Stokes
shift, high environment-independent fluorescence quantum yields, and sharp excitation and
emission peaks contributing to overall brightness. Many bio-molecules have been successfully
labeled with BODIPY moieties for countless research purposes.
Based on our past experience with tocopherol chemistry, we are now exploring the de-
velopment of a family of multi-scale imaging compounds related to the vitamin E family
combining F-18 PET radio-agent and BODIPY fluorescence. α-Tocopherol (αToc) is the
predominant member of the tocopherol family taken up by the human body. We have gener-
ated a F-18 BODPY labeled derivative, thienyl-ene-BODIPY-α-tocopherol (TB-Toc).11 In
this paper, we test whether such significant chemical alterations of αToc alters its effective
cellular uptake and low-toxicity. Furthermore, since αToc is a lipid and not water soluble,
the molecule is most effectively delivered by liposomal formulation. This opens up the pos-
sibility of antibody-guided targeting to specific cell types. We therefore also test TB-Toc’s
take-up and toxicity when delivered via liposome. Since αToc has few known receptors with
the exception, for example, of the a-tocopherol transfer protein, we hypothesize that the
cellular toxicity of TB-Toc will remain very low, with high take-up that allows for quality
fluorescent images.
For comparison’s sake, we include two non-fluorescent intermediate compounds, modified
at the αToc headgroup. These compounds are (2R)-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman
4
(H-toc) and (2R)-6-iodo-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman (I-toc) which
could be present in trace amounts in the clinical production and use of F-toc.
Results
Since future development of the molecules described here will employ live mouse models, we
focused on two murine cell lines, C2C12 mouse myoblasts and mouse embryonic fibroblasts
(MEFs). The two cell lines were cultured in the presence of each of the tocopherol derivatives
shown in Fig. 2 and a LUV-based delivery vehicle. In addition, the cellular uptake of the
TB-Toc derivative was studied to demonstrate the multiscale imaging capabilities of TB-Toc.
Viability of mouse cells cultured in the presence of tocopherol deriva-
tives
We monitored viability of C2C12 and MEFs in the presence of tocopherol derivatives (Fig.
3A and their synthetic precursors (Fig. 3B) at concentrations spanning five orders of mag-
nitude. The data in Figure 3 clearly show no sensitivity to tocopherol, 6-fluoro-tocopherol,
or the hydroxymethyl tocopherol (structures shown in Fig. 2) in either the C2C12 myoblasts
or the MEFs.
Furthermore, there was no evidence that either H-toc or I-toc were toxic at concentrations
up to 1mM. Interestingly, the data show a clear increase in absorption at 570 nm for both
myoblasts, suggesting a positive impact on the cell line.
Like the other tocopherol derivatives, TB-Toc was introduced to cell cultures of mouse
myoblasts and fibroblasts at concentrations ranging over five orders of magnitude (Fig. 4B &
C). Interestingly, the cultured myoblasts respond to the presence of TB-Toc. Unlike the other
examined tocopherol derivatives, the TB-Toc did begin to show some loss of live myoblasts
around 10-100 µM. It should be noted that 0.1 mM BODIPY-toc partially precipitated out
of solution when added to culture media; it completely precipitated out of solution at 1 mM
5
Figure 2: Structure of tocopherol, intermediates and derivatives.
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Figure 3: Viability of mouse cells cultured in the presence of tocopherol derivatives
at concentrations ranging from 1 nM to 1 mM. C2C12 mouse myoblasts and mouse
embryonic fibroblasts (MEFs) were treated with tocopherol derivatives (A) α-, F-, or HM-
tocopherol and (B) F-toc precursor molecules I- or H-tocopherol for 24h prior to assessing
viability via spectrophotometric measurement of formazan (absorbance at 570 nm) produced
from the live-cell-catalyzed reduction of MTT tetrazolium (i.e. MTT viability assay). There
were no significant differences between absorbance values of all tocopherol groups compared
to the corresponding vehicle control (0.1% DMSO; ANOVA followed by Tukey’s post-hoc
test). Data points represent means ± SEM, with n = 4 for all conditions except for F-toc
in MEFs (n = 3). Note: absorbance values for α-, F- and HM-toc vehicle control groups in
C2C12 cells and MEFs were 0.4343 ± 0.0299 and 0.2984 ± 0.0154, respectively. Absorbance
values for vehicle control groups for I- and H-toc in C2C12 cells and MEFs were 0.303 ±
0.002 and 0.151 ± 0.004, respectively.
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and was therefore not tested at this concentration.








0 . 7 B M E F








L U V  c o n c e n t r a t i o n  ( m g / m L )
A









 M E F








T B - t o c  c o n c e n t r a t i o n  ( n M )
1 0 0 1 0 1 1 0 2 1 0 3 1 0 4 1 0 5
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0 C
 M E F










T B - t o c  c o n c e n t r a t i o n  ( n m )










W a v e l e n g t h  ( n m )
Figure 4: Viability of mouse cells cultured in the presence of LUVs and BODIPY-
tocopherol. C2C12 mouse myoblasts and MEFs were treated with LUVs (A) and BODIPY-
tocopherol (B) prior to assessing viability via spectrophotometric measurement of formazan
(absorbance at 570 nm) produced from the live-cell-catalyzed reduction of MTT tetrazolium.
Data points represent means ± SEM (LUV: n = 8; TB-Toc: n = 2). (C) C2C12 and
MEFs were treated with BODIPY-tocopherol for 24h before determining the number of cells
excluding Trypan blue dye. Data points represent means ± SEM (n = 2). The number of
viable cells in the vehicle control groups for C2C12 cells and MEFs were 424,875 ± 31,125 and
249,000 ± 3,000 respectively.(D) TB-Toc absorption and emission spectra. Data reproduced
from Ghelfi et al.11
Viability of mouse cells cultured in the presence of LUVs
We prepared LUVs composed of POPC:POPG:Cholesterol:αToc (7:3:4:0.1) sized by extru-
sion of the hydrated lipid suspension through a 50 nm (diameter) pore. The effective hydro-
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dynamic radius of LUVs prepared in this manner was measured to be 81.9 nm as determined
by dynamic light scattering. This lipid composition is already applied to the clinically used
liposome-Doxorubicin suspensions.12 However, this composition lends itself to the expedi-
tious and simple incorporation. Specifically, the incorporation of the charged POPG which
makes extrusion of 50 nm easier, and avoids the presence of plauci-lamellar species (vesi-
cles composed of 2-3 bilayers).13 We monitored effects of LUVs on cell viability in both the
C2C12 cells and MEFs (Fig. 5) at concentrations spanning 3 orders of magnitude. The data
demonstrate that the LUVs are non-toxic up to 1 mg/mL and we can safely utilize the LUVs
at up to 0.1 mg/mL in both cell lines tested. Previous studies used 1 mg/mL of phospho-
lipids14 and 3 mM, which is approximately 2 mg/mL,15 in similar tests with cultured Chinese
hamster v79 cells and amoebae, respectively. In both cases, the concentrations examined
did not appear to harm the cells.
TBtoc Uptake
The newly synthesized MIA, TB-Toc,11 has a peak absorption at 571 nm with a smaller
peak at 530 nm and the emission spectra has a maximum fluorescence wavelength of 583
nm.11 We utilized the fluorescence properties of TB-Toc to monitor its uptake into cells.
TB-Toc was delivered to the cells using two methods, in DMSO stock solutions or in
LUVs. TB-Toc was introduced to the cultures at approximately the same concentration of
our MIA. Figure 5 illustrates the time-depended uptake of TB-Toc delivered to MEFs via
LUVs. The data show that TB-Toc uptake is completed in approximately 30 minutes, with
no observable distress to the cells. Similar results were observed for DMSO delivered TB-Toc
(SI), where uptake was complete in 30 minutes. However, LUV delivery yields faster initial
uptake, compared to DMSO, demonstrated by the analysis of overall intensity at each time
point (Fig. 5C). The observation that LUV delivery yields faster initial uptake, compared to
DMSO, is further visualized by the overall intensity of the images at 5 minutes after delivery
(see SI).
9
Figure 5: Cellular uptake of BODIPY-tocopherol. (A) MEF uptake of TB-Toc deliv-
ered with LUVs.Top row are fluorescence images (Ex. 587 nm; Em. 610 nm); the bottom row
are the brightfield images. (B) Fluorescence intensity of TB-Toc in C2C12 cells delivered via
DMSO and LUVs after 40 min. of incubation. Images are maximum projections of z-stacks
taken at 0.32 nm intervals. (C) The relative fluorescence intensity of TB-Toc introduced to
MEF cells via LUVs (red circles) and DMSO (black squares) and introduced to C2C12 cells
via LUVs (blue triangles).
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The overall intensity of the LUV delivered label is fainter than the DMSO solution, Fig.
5 B. However, the images suggest that delivery via DMSO and LUVs yield the same cellular
distribution of TB-Toc. We suspect the brightest spots are lipid droplets, however, without
co-localization studies this cannot be confirmed. Nevertheless, our data clearly demonstrate
substantial cellular uptake of our MIA.
Discussion
Currently, the majority of PET imaging is performed using FDG (18F-fluorodeoxyglucose),
a glucose analogue attached to a PET radiotracer (Fluorine-18). FDG targets cancer in
a non-specific manner relying on the enhanced rate of glucose metabolism in fast-growing
tumour cells and the slow metabolism of the deoxyglucose. The ability to incorporate 18F
radio tracers onto F-toc and TB-Toc provide a new opportunity for the area of PET imaging.
Our data support the application of F-toc as a PET imagining agent. Neither the F-
toc nor the tocopherol-based precursors show cytotoxicity up to a concentration of 1 mM,
suggesting excellent tolerance by mammalian cells. In addition, these new molecules are
relatively easy to synthesize: the two synthetic pathways to produce F-toc, either by elec-
trophilic fluorination or nucleophilic fluorination, can be completed in under 15 minutes (see
Methods and Materials). This expedient synthesis addresses the technical issues of optimized
and expedient production of the F-18 labeled agent since F-18 has a short half-life of 109
minutes.
The toxicity of our TB-Toc seems to be qualitatively comparable to BODIPY-cholesterol.
Although we were not able to find quantitative toxicity data for BODIPY-cholesterol in cell
lines, many have reported that cells and organisms remain undisturbed with no significant
delay in cell growth when incubated with BODIPY-cholesterol.16,17
Our presented LUV composition lacks the targeted specificity that many existing li-
posomal technologies offer, however it does avoid complications caused by incorporating a
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polyethylene glycol coating, namely foot-mouth syndrome.18 However, the presented tocopherol-
inspired molecules toned not be delivered in the LUV composition chosen in this work. The
absorption and distribution of tocopherol is well understood,19–22 and the vast majority of
tocopherol exists in cell membranes. Thus, targeted delivery of tocopherol and its derivatives
using liposomal delivery vehicles should allow targeting of the new MIA to specific cell and
tissue types utilizing the plethora of existing targeted liposome systems,23–25 some of which
are already clinically approved targeted lipid-based delivery technologies.25
Alternatively, delivery of tocopherol inspired agents without the use of a targeted LUV
carrier will also prove clinically useful. The known ability of the probe to bind with high
affinity to the α-tocopherol transfer protein (α-TTP) assures that the probe will be taken up
with specificity by the liver, where α-TTP is abundant. The imaging of liver is particularly
important at present given the growing prevalence of non-alcoholic fatty liver (NAFL) and
non-alcoholic steatohepatitis (NASH), pathologies common in obese and diabetic patients.
Available diagnostic and prognostic tools for NAFL are very poor, both in terms of clinical
timing, sensitivity and selectivity on disease mechanisms.26,27 Studies have demonstrated
the potential for vitamin E in the prevention of NASH, such clinical guidelines are now
recommending vitamin E as a first line therapy for non-diabetic adults with biopsy-proven
NASH.28–30
Although much emphasis has been placed on the PET applications of our imaging agents,
precedence has been set for the use of liposomes as diagnostic agents using the SPECT
technique as PET and SPECT go hand in hand with cost and benefit.31,32 Some of our
precursor molecules, namely I-toc, could be used as a SPECT agent. The isotope 125I has
been used to synthesize β-, γ- and δ- tocopherols in the past.33 However, 123I is more common
in imaging since it has a shorter half life (13.22h h) than 125I (60 days) or 131I (8 days), but
all three isotopes would be viable candidates for a SPECT agent and the optimal isotope
depends on the application.
There have not been many SPECT agents to monitor liposomal delivery via the lipo-
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somal membrane, rather, they use Technecium-99m, Indium-111.34 Metals have there own
toxicological issues, are much more unnatural to the body than iodide (iodine is in thyroid
glands, etc.) and need chelating agents to be bound to the liposome. We have demonstrated
that our I-toc is not toxic. If the I-toc were to degrade by oxidation, it would form I− and
tocopherol and/or tocopherol-quinone. Since αToc is often added to protect liposomal de-
livery systems,12 the I-toc would be relatively safe from degradation. Further, SPECT and
PET can be imaged at the same time; thus, a liposome mixture of 18F-toc and I-toc could
allow for SPECT/PET images to be collected simultaneously.35
Conclusion
The present work presents a molecule that has the desired properties of an imaging fluo-
rophore while also serving as a PET agent. Furthermore the technology can be used for
both purposes simultaneously. The dual-modality probe (PET and fluorescence) presented




C2C12 mouse myoblasts, Dulbecco’s Modified Eagle Medium (DMEM; with high glucose, L-
glutamine, sodium pyruvate, and sodium bicarbonate), Eagle’s minimum essential medium
(MEM) non-essential amino acids solution, penicillin/streptomycin solution, fetal bovine
serum (FBS), and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-
Aldrich (St. Louis, MO). Mouse embryonic fibroblasts (MEFs) were purchased from ATCC
(Manassas, VA). 96-well cell culture microplates (polystyrene, clear flat-bottom) were pur-
chased from Greiner Bio-One (Frickenhausen, Germany). 6-well cell culture plates were
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purchased from Sarstedt (Newton, SC). Dimethyl sulfoxide (DMSO) was purchased from Bio-
Shop (Burlington, ON, Canada).1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0/18:1
PC, POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine [16:0/18:1 PC, POPC], and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt) [16:0/18:1 PG, POPG]
were purchased from Avanti Polar Lipids (Alabaster, AL) and used as received. Unless oth-
erwise indicated, all other materials were purchased from Sigma-Aldrich (St. Louis, MO,
USA), BioShop (Burlington, ON, Canada), or Fisher Scientific (Mississauga, ON, Canada).
Synthesis of F-Toc by electrophilic fluorination
H-Toc (1eq) was mixed with N-fluorobenzenesulfonimide (1eq) and stirred in dry acetonitrile
as a 1M solution for 10-15min at 150◦C. The reaction was cooled to room temperature,
extracted with CH2Cl2 and water, the organic phase dried over Na2SO4 and evaporated
down to dryness. The crude product was filtrated trough a silica plug with hexane to remove
polar byproducts. Silica column chromatography (gradient Hexane to Hexane/CH2Cl2 99:1)
afforded F-Toc (44%) as a clear oil.
To a 0.85M solution of I-Toc (1eq) in dry THF at 0◦C under an N2 atmosphere was a 1.7M
t-BuLi solution in pentane (2eq) added and stirred for 1min. An 0.35M N-fluorobenzenesulfonimide
(2eq) solution in THF was slowly added and stirred for 1min at 0◦C. The reaction was
quenched with methanol, the solvents evaporated, extracted with CH2Cl2 and water, the
organic phase dried over Na2SO4 and evaporated down to dryness. Silica column chro-
matography (gradient Hexane to Hexane/CH2Cl2 99:1) afforded F-Toc (15%) as a clear oil.
This strategy was adapted from previously reported methods.36,37
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Synthesis of F-Toc by nucleophilic fluorination
(Phenyl)tocopherol iodonium tosylate prepared by previously reported methods (1eq),38 was
dissolved in DMF as a 5mM solution, 1M tetrabutylammonium fluoride in THF (1M TBAF
in THF, 1eq) was added and stirred for 15min at 150◦C. The solvent was evaporated to
dryness and the residual mixture partitioned between hexane and water. The organic phase
was dried with Na2SO4, filtrated and purified over a small SiO2 column with hexane. Silica
column chromatography (gradient Hexane to Hexane/CH2Cl2 99:1) afforded F-Toc (24%) as
a clear oil.This synthetic strategy was adapted from previously reported methods.39
TLC: Rf = 0.27 (Hexane) 1H-NMR (400MHz, CDCl3): δ 2.60 (t, J = 6.80 Hz, 2H,
ArCH2CH2), δ 2.16 (d, J = 6.80 Hz, 3H, ArCH3), δ 2.12 (d J = 1.60 Hz, 3H, ArCH3), δ
2.11 (s, 3H, ArCH3), δ 1.81 (enant. dt, J = 6.80 Hz, 2H, ArCH2CH2), δ 1.65-1.04 (m, 21H,
phytyl-CH/CH2 + 2’R-CH3) δ 8.88 (m, 12H, phytyl-CH3)
13C-NMR (100MHz, CDCl3): 154.45, 152.13, 147.07, 147.06, 123.10, 123.06, 121.41,
121.22, 119.08, 118.90, 117.60, 117.56, 74.91, 39.86, 39.77, 39.38, 37.57, 37.53, 37.45, 37.40,
37.33, 37.29, 32.79, 32.69, 31.26, 31.20, 29.71, 27.99, 24.82, 24.45, 23.81, 22.73, 22.63, 21.02,
20.36, 20.34, 19.75, 19.69, 19.64, 19.60 19F-NMR (400MHz, CDCl3): -131.49, -131.50 (d,
J = 4 Hz, 1F, Ar-F) MS [EI+] m/z 432.49 (M, 10%), m/z 205.18 (100%), HRMS Calculated
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for C29H51NO 429.3971; found: 432.3762
Synthesis of TB-Toc
TB-Toc was synthesized following previously reported methods.11
Cell Culture
C2C12 mouse myoblasts and mouse embryonic fibroblasts (MEFs) were cultured in DMEM
supplemented with 10% (v/v) FBS, 4500 mg/L glucose, 4 mM L-glutamine, 1 mM sodium
pyruvate, 2% (v/v) MEM nonessential amino acid solution, and penicillin (50 I.U./mL) /
streptomycin (50 µg/mL) solution (complete media). Cells were cultured in a humidified
5% CO2 atmosphere within a Thermo Forma Series II water-jacketed CO2 incubator main-
tained at 37◦C. Cells were transferred to fresh 96- or 6-well plates (2,000 cells/well & 60,000
cells/well, respectively) in the evening prior to commencing tocopherol treatments.
Liposome stock solutions and cell treatments
Phospholipid films were prepared by transferring the desired volumes of stock solutions of
POPC:POPG:Cholesterol:αToc (or TBtoc), at a molar ratio of 7:3:4:0.1, to a glass vial.
Organic solvent was then removed with an N2 stream and gentle heating, followed by drying
in vacuo (≥6 h). Lipid films were hydrated with phosphate buffered saline (pH 7.4) to
a concentration of 10 mg/mL. The resulting multilamellar vesicle (MLV) suspensions were
incubated at 30◦C and subjected to five freeze/thaw cycles. Large unilamellar vesicles (LUVs)
were prepared by passing the MLV suspensions through a single use sterile 50 nm NanoSizer
(T&T Scientific, Knoxville, TN) 31 times at room temperature.
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Tocopherol stock solutions and cell treatments
Each tocopherol was dissolved in sterile 100% DMSO to yield a 1 M stock solution. Less
concentrated stock solutions were subsequently prepared using ten-fold serial dilutions. All
tocopherol solutions were stored at -20◦C. To treat cultured cells, media was replaced with
complete media containing freshly-added tocopherol; the final amount of vehicle (DMSO)
for all concentrations tested was 0.1% (v/v).
MTT tetrazolium reduction assay
Media was discarded, wells were washed once with phenol red-free complete culture media,
and 100 µL/well phenol red-free complete culture media containing 0.45 mg/mL MTT was
added. Two hours later, solubilization solution [40% (v/v) dimethylformamide, 2% (v/v)
glacial acetic acid, 16% (w/v) sodium dodecyl sulfate, pH 4.7] was added (100 µL/well)
and well contents were gently mixed by re-suspension to dissolve the formazan precipitate.
Plates were incubated at room temperature in darkness for 2h before recording absorbance
at 570 nm using a Bio-Tek PowerWave Microplate UV-Vis spectrophotometer (Winooski,
VT, USA). For each plate, background signal averaged from cell-free wells containing vehicle
treatments was subtracted.
Trypan blue exclusion assay
Media was discarded, wells were washed once with phosphate-buffered saline, and cells
were harvested via trypsinization. After centrifugation (240 g, 3 min), cell pellets were re-
suspended in complete culture media and subsequently diluted in 0.4% (w/v) Trypan Blue
solution. Three minutes later, the numbers of viable (non-stained) cells were counted using
a hemocytometer (Hausser Scientific, Horsham, PA) viewed under a Hund Wetzlar Wilovert
Inverted Phase-Contrast light microscope (Fisher Scientific, Mississauga, ON, Canada).
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Live-cell fluorescence microscopy
Fluorescence imaging of live cells was performed using Zeiss Axio Observer.Z1 inverted
light/epifluorescence microscope equipped with ApoTome.2 optical sectioning, a Plan-Apochromat
63x/1.40 Oil DIC M27 objective lens, and a Hamamatsu ORCA-Flash4.0 V2 digital camera.
Both the intensity of fluorescence illumination achieved via an X-Cite 120LED light source
and camera exposure times were held constant between experiments. BODIPY fluorescence
was viewed using excitation and emission wavelength filter sets of 540 – 552 nm and 590 –
660 nm, respectively, with set excitation and emission wavelengths of 587 nm and 610 nm, re-
spectively (Zeiss Item# 411003-0010-000). Z-stack series consisted of approximately 20 – 40
slices taken at 0.32 µm intervals and were rendered into 2D maximum intensity projections
using the ‘extended depth of focus’ processing tool in Zeiss Zen 2 (blue edition) microscopy
software. The microscope stage and objective were maintained at 37◦C using a TempModule
S-controlled stage heater and objective heater (PeCon, Erbach, Germany). A humidified 5%
CO2 environment was achieved via tubing connected to a humidified CO2 culture incubator.
One day prior to imaging, cells were seeded onto MatTek poly-D-lysine-coated glass bottom
culture dishes in complete culture media devoid of phenol red.
Fluorescence intensity was analyzed from the microscope images using the ImageJ soft-
ware.40,41
Statistical Analyses
Data sets were analyzed in GraphPad Prism 5 using one-way ANOVA and Turkey’s post-hoc
test, with a p-value of less than 0.05 considered significant.
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